Astrazeneca invests $2bn in cancer drug tie-up Markets Astrazeneca has invested $2bn in US pharmaceutical firm Summit Therapeutics as part of a blockbuster cancer research tie-up. The FTSE 100 drugs giant has agreed to buy 109,000 shares in Nasdaq-listed Summit for $18.36 per share as part of the deal. Shares in Astrazeneca jumped by 1.4 per cent to 12,664p in early trading. The tie-up [...]
Astrazeneca share price tumbles on $400bn megamerger talks Investing Astrazeneca’s share price slumped sharply on Monday as investors baulked at a potential $400bn megamerger with US rival Bristol Myers Squibb. Shares in the UK drugmaker slid six per cent in early trading to 11,866p after the Financial Times reported it has been holding talks regarding a potential tie-up with the US group in recent [...]
Boots eyes £7.5bn sale in blow to hopes of London IPO Retail The owners of Boots are weighing up a £7.5bn sale which would dash hopes of a London listing and deal another blow to the UK’s stock exchange. Sycamore Partners, the private equity firm which bought Boots’ parent company for $23.7bn last year, has been in talks with a number of suitors since before Easter. The [...]
GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares June 9, 2026 GSK has said agentic AI is already affecting every asset in its pipeline, as pharmaceutical firms race to use the technology to cut the cost and risk of developing new medicines. Speaking at London Tech Week in Tuesday, Eyal Itskovits, GSK’s director of AI and machine learning, said that the technology has officially become a [...]
GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn June 9, 2026 Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent. The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was trading at just before this announcement. The deal is expected to officially close [...]
Astrazeneca ploughs £300m into UK in surprise U-turn April 29, 2026 British drugs giant Astrazeneca has promised to plough £300m into its UK operations, just months after cancelling a nine-figure investment in a new lab after getting in a spat with the UK government over drug pricing. In a stunning volte-face, the UK’s largest pharmaceutical company said it would revive its £200m investment into a megalab [...]
Haleon takes hit from ‘weak cold and flu season’ but Sensodyne shines April 29, 2026 After being spun out from GSK in the biggest London IPO in decades, City analyst are looking for more from the emblematic FTSE 100 consumer healthcare powerhouse with roots in a Lombard Street apothecary shop Fewer sniffles during the winter have sent a chill through sales volumes at Haleon, the FTSE 100 over-the-counter remedy maker. [...]
Novo Nordisk shares tumble after drug trial falls short February 23, 2026 Shares in Danish drug giant Novo Nordisk have shed more than a sixth of their value after poor drug trial results sparked an investor selloff. The firm behind weight-loss drugs Ozempic and Wegovy saw its shares tumble by 16.7 per cent to 257.23 Danish Krone on Monday morning after trials of its new obesity shot, [...]
Exclusive: NHS must keep medicine clawback down or lose investment, says weight-jab boss February 18, 2026 The NHS must keep its medicines clawback tax low and predictable or else risk disrupting the rollout of weight-loss drugs in the UK, Novo Nordisk’s UK chief has said. Sebnem Avsar Tuna, general manager of UK operations for the Ozempic and Wegovy maker, told City AM the Government must keep in place the current ceiling [...]
Hikma: FTSE 100 giant’s boss replaced by former chief after share price woes December 15, 2025 The boss of FTSE 100 giant Hikma Pharmaceuticals will be replaced by the firm’s former top chief after the group’s share price dropped by nearly a quarter this year. Riad Mishlawi has exited his role as chief executive at Hikma, with executive chairman Said Darwazah to step into the post with “immediate effect”. It ends [...]